Columbia University receives $2.75 million for Alzheimer's and Parkinson's disease research

May 21, 2002

The Japanese trading firm Marubeni has given Columbia University $2.75 million to support research in age-related neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, using a technique that quantifies gene expression in brain tissue.

"It has become clear in the past two decades that advances in medicine that promote longevity increase a person's risk for age-associated neurodegenerative disorders such as Alzheimer's and Parkinson's diseases," says Dr. Michael Shelanski, Delafield Professor of Pathology and Chairman of the Department of Pathology at Columbia University College of Physicians & Surgeons and co-investigator on the project. "We believe our methodology will help us find new targets in the brain to help prevent and treat these disorders."

The research aims to look at differences in gene expression in diseased vs. healthy brain tissue. The researchers will use Serial Analysis of Gene Expression, or SAGE, a method that tracks gene expression in cells by creating unique identifying tags from each gene transcript and then submitting all the tags to high-throughput sequencing. "By comparing transcripts from tissue of Alzheimer's and Parkinson's disease patients to healthy tissue, we aim to find those genes associated with neuronal cell death," says Dr. Lloyd Greene, professor of pathology at P&S and co-investigator on the project. "Once identified, the genes could be potential targets for therapeutic drug development."

"We are pleased to establish this important business collaboration with Columbia University, which will help deepen the activity of the Marubeni Corporation for the emerging industries in the United States as well as Japan," says Kazuo Ogawa, director of Marubeni.

"Columbia has a strong background in technology transfer and licensing opportunities- ranking first among U.S. universities for the past three years," says Ofra Weinberger, director of Science and Technology Ventures, Columbia's technology transfer division. "Marubeni's interest in supporting our research and technology development opens the door for other Japanese companies and individual investors to further the growth of emerging industries."

In addition to the $2.75 million for research finding genes associated with neuronal cell death using SAGE technology, Marubeni has agreed to lead an investment fund that will provide capital for Columbia University's technology transfer and commercialization efforts in emerging industries such as health sciences and nanotechnology. The initial capitalization of the Marubeni fund is expected to be more than $20 million. A Memorandum of Understanding has been signed and the fund is expected to be established later this year.

Columbia University Medical Center

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to